Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic cytokine-induced memory-like NK cells WU-NK-101

A population of off-the-shelf (OTS) donor-derived cytokine-induced, memory-like, cytotoxic natural killer (NK) cells (CIML NKs) containing NK cell-activating surface receptors, with potential immunomodulating and antineoplastic activities. The allogeneic NK cells are pre-activated ex vivo using the human-derived cytokines interleukin (IL)-12, IL-15, and IL-18, which induces the differentiation of the NK cells into CIML NK cells, which contain more NK cell-activating surface receptors. The pretreated NK cells exhibit enhanced activation and increased production of the cytokine interferon-gamma (IFN-g), and may exert enhanced cytotoxicity against tumor cells, including enhanced antibody-dependent cellular cytotoxicity (ADCC). Upon administration, the CIML NKs WU-NK-101 may induce an anti-tumor immune response and kill tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CIML NKs WU-NK-101
donor-derived CIML NKs WU-NK-101
Code name:WU-NK 101
WU-NK-101
WU-NK101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search